Introduction {#s001}
============

F[or patients with type]{.smallcaps} 2 [diabetes]{.smallcaps} who require insulin therapy, continuous subcutaneous insulin infusion (CSII) provides a potential alternative to multiple daily injections (MDI) for insulin delivery.^[@B1]^ However, although the use of CSII has been well documented in type 1 diabetes, relatively few studies with this therapy in type 2 diabetes have been published to date.^[@B1],[@B2]^ The recent OpT2mise study was a randomized controlled trial that compared the efficacy of CSII and MDI in patients with type 2 diabetes who had previously been unable to reach glycated hemoglobin (HbA~1c~) targets despite using intensified MDI regimens.^[@B3]^ After 6 months, there was a significant between-group treatment difference of −0.7% (7.7 mmol/mol) in HbA~1c~ levels, favoring the use of CSII, with no increase in the risk of hypoglycemia.^[@B3]^

HbA~1c~ is the glycemic control marker most linked to complications of diabetes and remains the key target of disease management.^[@B4]^ However, it does not fully characterize day and night glucose profiles, which are needed to understand how best to adjust treatment, particularly insulin therapy. The use of continuous glucose monitoring (CGM) provides the opportunity to observe glycemic patterns over specified time periods,^[@B5],[@B6]^ and blinded CGM can be used to help determine glycemic variability, providing valuable information on the effectiveness and safety of experimental interventions.^[@B7]^ To date, however, few studies have investigated the use of CGM in patients with type 2 diabetes receiving intensive MDI or CSII therapy.^[@B8],[@B9]^ For this reason, a secondary objective of the OpT2mise study was to compare the effects of CSII and MDI on glucose profiles obtained using CGM data in patients with suboptimally controlled type 2 diabetes. The results of this analysis are reported here.

Research Design and Methods {#s002}
===========================

OpT2mise was a multicenter, international, randomized, controlled, parallel-group study to evaluate the comparative efficacy and safety of CSII and MDI regimens in insulin-using patients with type 2 diabetes that was suboptimally controlled with advanced basal--bolus therapy. It was performed at 36 centers in Canada, Europe, Israel, South Africa, and the United States, and all patients provided written informed consent.

The study methods have been reported in full elsewhere.^[@B3],[@B10]^ In brief, subjects with poor glycemic control (*n*=495) on MDI were enrolled into a run-in period for insulin dose optimization (≥0.7 and ≤1.8 U/kg/day), after which those in whom control remained suboptimal (HbA1c≥8% \[64 mmol/mol\] and ≤12% \[108 mmol/mol\]) were randomly assigned to receive CSII or continued MDI for 6 months. Blinded CGM data were obtained using the Medtronic *i*Pro2™ CGM system (Medtronic, Northridge, CA), with glucose data recorded over 6 days before randomization (at the end of the run-in intensification period, referred to as baseline) and on completion of 6 months of randomized treatment. The mean absolute relative difference of the sensors was calculated.

The primary end point of the study was the between-group difference in change in mean HbA~1c~ from baseline to the end of the randomized phase. Secondary end points included changes from baseline to 6 months in CGM parameters, including mean 24-h glucose levels, the area under the curve for hypoglycemia (defined as sensor glucose \[SG\] values ≤70 mg/dL) and hyperglycemia (SG values ≥180 mg/dL), and the time spent in hypoglycemia and hyperglycemia. Areas under the curve were calculated as the product of the magnitude and duration of sensor-measured glucose values above or below the specified thresholds. Information on glucose variability, including SD, mean amplitude of glucose excursions, and continuous overlapping net glycemic action (CONGA) (over a 60-min interval), was also collected as a secondary end point. In addition, the impact of CSII on postprandial (4-h) glucose profiles was evaluated. For this analysis, breakfast time was arbitrarily defined as ranging from 06:00 to 09:00 h inclusive, lunch time from 11:30 to 15:00 h inclusive, and dinner time from 16:30 to 22:30 h inclusive, in order to accommodate differences in meal patterns between countries.

Statistical analysis {#s003}
--------------------

The full description of the statistical plan of the OpT2mise trial has been published in detail elsewhere.^[@B10]^ The present analysis of glucose profiles was based on available CGM data, with no imputation of missing values. In order to maximize the consistency of CGM data, only data from at least two consecutive 24-h periods of CGM were included in the analysis. Continuous end points were analyzed with a two-sided, two-sample, *t* test. Analyses were performed with SAS version 9.3 software (SAS Institute, Cary, NC), and *P* values \<0.05 were considered to be statistically significant.

Results {#s004}
=======

In total, 590 patients were assessed for eligibility, of whom 495 entered the 2-month run-in phase during which insulin dosage was optimized. Of these, 331 had suboptimal glycemic control, defined as an HbA~1c~ level of ≥8% (64 mmol/mol) and ≤12% (108 mmol/mol), at the end of the run-in phase and were randomized to CSII (*n*=168) or continued MDI (*n*=163). Baseline characteristics of the randomized patients are summarized in [Table 1](#T1){ref-type="table"}. The mean (±SD) age was 56.0±9.6 years, the mean duration of diabetes was 15.1±8.0 years, and mean HbA~1c~ level was 9.0±0.8% (75±8.7 mmol/mol).

###### 

[Baseline Characteristics of Randomized Subjects]{.smallcaps}

                                         *CSII*                *MDI*
  -------------------------------------- --------------------- ---------------------
  Number of patients                     168                   163
  Age (years)                            55.5±9.7              56.4±9.5
  Gender (men/women)                     94/74 (56.0%/44.0%)   86/77 (52.8%/47.2%)
  Duration of diabetes (years)           14.9±8.0              15.3±8.0
  Body mass index (kg/m^2^)              33.5±7.5              33.2±7.0
  HbA1c \[% (mmol/mol)\]                 9.0±0.8 (75±8.7)      9.0±0.8 (75±8.7)
  Total daily insulin dose (units/day)                         
   Long-acting                           57.4±30.3             52.4±27.7
   Rapid-acting                          55.6±31.7             53.8±30.8
  Insulin dose (units/kg/day)            1.1±0.4               1.1±0.4
  Metformin use                          120 (71%)             112 (69%)
  Metformin dose (mg)                    1,810±680             1,788±636

Data are presented as mean±SD values or as number (percentage), as indicated.

CSII, continuous subcutaneous insulin infusion; HbA~1c~, glycated hemoglobin; MDI, multiple daily injections.

As previously described,^[@B3]^ at 6 months the mean HbA~1c~ level had decreased to 7.9% (63 mmol/mol) in the CSII group (mean change, −1.1±1.2% \[−12.0±13.1 mmol/mol\]) and to 8.6% (70 mmol/mol) in the MDI group (mean change, −0.4±1.1% \[−4.4±12.0 mmol/mol\]). The between-group difference was statistically significant in favor of CSII (−0.7%; 95% confidence interval \[CI\], −0.9, −0.4% \[−7.7 mmol/mol (95% CI, −8.6, −4.4 mmol/mol)\]; *P*\<0.001).

At baseline, blinded CGM data were available for 125 patients in the CSII group (74.4%) and 135 (82.2%) in the MDI group; the corresponding values at 6 months were 108 (64.3%) and 101 (62.0%), respectively. Baseline mean absolute relative difference of blinded sensors was 11.2±6.2% and 10.7±5.4% in the CSII and MDI groups, respectively; the corresponding values at 6 months were 12.9±5.6% and 12.0±7.9%, respectively. The baseline characteristics of patients with available CGM data did not differ significantly from those of the overall randomized population.

The mean daily number of self-monitoring blood glucose (SMBG) measurements at baseline was 4.1±1.2 in the CSII group and 4.1±1.2 in the MDI group; the corresponding values at 6 months were 4.7±2.0 and 4.2±1.7, respectively. There were no significant between-group differences in the change in the mean number of SMBG measurements from baseline (*P*=0.079).

Changes in SG data from baseline to 6 months are summarized in [Table 2](#T2){ref-type="table"}. Compared with the MDI group, patients receiving CSII showed significantly greater reductions in 24-h mean SG (mean treatment difference, −17.1 mg/dL; *P*=0.0023), less time of exposure to SG \>180 mg/dL (−12.4%; *P*=0.0004) and SG\>250 mg/dL (−5.5%; *P*=0.0153), and more time with SG within the target range of 70--180 mg/dL (12.3%; *P*=0.0002). There was no difference in time with exposure to SG\<70 mg/dL between the groups.

###### 

[Changes in Continuous Glucose Monitoring Variables from Baseline to 6 Months]{.smallcaps}

                                                      *CSII*         *MDI*         *Between-group difference*
  --------------------------------------------------- -------------- ------------- ----------------------------------------
  Change in 24-h mean glucose concentration (mg/dL)   −23.0±42.6     −5.9±30.2     −17.1^[a](#tf4){ref-type="table-fn"}^
  AUC change \>180 mg/dL (mg/dL/min)                  −11.5±25.5     −2.2±15.8     −9.3^[a](#tf4){ref-type="table-fn"}^
  Change in time spent \>180 mg/dL (min/24 h)         −225.6±355.9   −56.8±256.3   −168.7^[b](#tf4){ref-type="table-fn"}^
  AUC change \<70 mg/dL (mg/dL/min)                   0.0±0.5        −0.1±0.9      0.1 (NS)
  Change in time spent \<70 mg/dL (min/24 h)          8.8±49.6       5.1±71.0      3.7 (NS)

Data are mean±SD values.

*P*\<0.01, ^b^*P*\<0.001.

AUC, area under the curve; CSII, continuous subcutaneous insulin infusion; NS, not significant.

Similar results were obtained when the analyses were adjusted by the number of SMBG measurements performed both during the whole study phase (6 months) and during the time that the blinded CGM data were collected.

There were no significant differences in measures of glucose variability between the groups. The mean change in 24-h SG SD from baseline to 6 months was −3.9±13.9 mg/dL (95% CI, −6.8, −1.0) in the CSII group, compared with −3.6±14.2 mg/dL (95% CI, −6.6, −0.6) in the MDI group. Similarly, the mean changes in mean amplitude of glucose excursions from baseline to 6 months were −5.2±35.6 (95% CI, −12.7, 2.3) and −8.8±33.4 mg/dL (95% CI, −15.8, −1.8), respectively. The mean changes in CONGA from baseline to 6 months were −2.3±10.3 in the CSII group and −1.8±9.9 mg/dL in the MDI group (between-group difference, −0.55 \[95% CI, −3.47, 2.36\]; *P*=0.71). CGM data at baseline and at 6 months are summarized in [Figure 1](#f1){ref-type="fig"}, which presents a visual representation of the modal day, in which all collected data over multiple days are shown over a single 24-h period, starting and ending at midnight. [Figure 1](#f1){ref-type="fig"} shows that, at 6 months, CSII resulted in decreases in median SG values during the night, postbreakfast, during the late afternoon, and postdinner, compared with MDI.

![Visual representation of the modal day, in which all collected data over multiple days are shown over a single 24-h period, starting and ending at midnight. **(Upper panels)** Median daily blood glucose concentrations **(left)** at baseline and **(right)** after 6 months, in relation to the "normal" range (70--180 mg/dL), which is indicated by the dashed lines. **(Lower panels)** Daily blood glucose variability **(left)** at baseline and **(right)** after 6 months. The light gray area represents the interquartile range (25^th^ and 75^th^ percentiles) for the multiple daily injections (MDI) arm, whereas the corresponding range for the continuous subcutaneous insulin infusion (CSII) arm is shown in transparent dark gray (middle part of the plot); the interquartile ranges from both arms have been superimposed to facilitate visual comparisons. The black and gray lines at the bottom represent the 10^th^ percentile for the CSII and MDI arms, respectively, and the corresponding lines at the top represent the 90^th^ percentile for the CSII and MDI arms, respectively.](fig-1){#f1}

The evaluation of postprandial glucose profiles showed that the decrease in 4-h postprandial hyperglycemia, measured as the area under the curve≥180 mg/dL, was significantly greater with CSII than with MDI after breakfast (−775.9±1,441.2 mg/dL/min vs. −160.7±1,074.1 mg/dL/min, respectively; *P*=0.0015) and after dinner (−731.4±1,580.7 mg/dL/min vs. −71.1±1,083.5 mg/dL/min, respectively; *P*=0.0014); the difference in area under the curve after lunch did not reach statistical significance (−465.0±1,565.0 mg/dL/min vs. −180.0±1,272.0 mg/dL/min). There was no significant difference between the groups in the change in 1-h postprandial CONGA from baseline (between-group difference, −1.6 \[95% CI, −4.7, 1.6\] at breakfast, −1.0 \[95% CI, −4.4, 2.5\] at lunch, and 0.6 \[95% CI, −2.6, 3.9\] at dinner).

Discussion {#s005}
==========

The results of this analysis show that, compared with basal--bolus therapy with insulin analogs, CSII treatment in suboptimally controlled patients with type 2 diabetes provides a significant improvement in glucose profile, with increased time spent in the target glucose range, without increasing the time spent in hypoglycemia.

In routine clinical practice, assessment of glycemic control is typically performed using HbA~1c~ in combination with fasting blood glucose and capillary SMBG profiles.^[@B11]^ Blinded CGM allows a more detailed glucose profile to be constructed, which overcomes the limitations of intermittent and sometimes unrepresentative data provided by SMBG.^[@B6],[@B12]^ OpT2mise is one of the few comparative studies of CSII and MDI in patients with type 2 diabetes that includes data on glycemic control as measured by CGM.^[@B8],[@B9]^ This analysis from OpT2mise showed that the time spent in the glucose target range commonly used in clinical practice (70--180 mg/dL) was significantly higher in patients using CSII than in those using MDI. The observed 17 mg/dL reduction in 24-h mean SG concentrations seen in the CSII group is consistent with the 0.7% (7.7 mmol/mol) difference in HbA~1c~ level at 6 months.^[@B13]^ In addition, patients using CSII had significantly less exposure to hyperglycemia, defined as glucose concentrations above 180 mg/dL or 250 mg/dL.

An important concern relating to the intensification of insulin therapy in patients with type 2 diabetes is the increased risk of hypoglycemia.^[@B14],[@B15]^ In addition to being a cause of morbidity and worsening quality of life, recurrent hypoglycemia may compromise the long-term maintenance of glycemia.^[@B16]^ It is important that, in this study, the reduction in exposure to hyperglycemia in the CSII group was not associated with an increase in time spent in hypoglycemia (SG\<70 mg/dL). Furthermore, as described previously,^[@B3]^ there was only one episode of severe hypoglycemia during the study, which occurred in the MDI group.

In addition to reductions in HbA~1c~ and SG, CSII was also associated with attenuation of postbreakfast and postdinner glucose concentrations. In epidemiological studies, high postprandial glucose concentrations have been associated with cardiovascular morbidity and mortality^[@B20]^; as a result, although the clinical significance of this relationship is still a matter of debate,^[@B21],[@B22]^ control of postprandial glucose profiles is an objective of antidiabetes therapies in type 2 diabetes.^[@B11],[@B23]^ When using MDI, this requires three or more daily injections of rapid-acting insulin analogs at mealtimes, whereas with CSII bolus insulin administration is required. In OpT2mise, the impact of pump therapy on postprandial glucose control, compared with MDI, was evaluated by measuring glucose concentrations over arbitrarily defined time frames for breakfast, lunch, and dinner, in order to allow for differences in mealtimes between the participating countries. The reason for the minimal effect of CSII on postlunch glucose excursions, compared with the significant reductions seen after breakfast and dinner, is unclear from this study and should be further assessed. Relevant factors may include differences in meal composition or bolus insulin doses, or omission of lunchtime insulin doses.

Glucose variability, as assessed by SD, mean amplitude of glucose excursions, and CONGA, improved to similar extents in both groups. This finding could be related to the lower glucose variability in patients with insulin-treated type 2 diabetes, compared with patients with type 1 diabetes,^[@B24],[@B25]^ and to differences in the approach to pump therapy and overall management in the two settings. It does not preclude the possibility that patients with type 2 diabetes with less insulin resistance might benefit from a reduction in glucose variability with CSII, as has been seen in patients with type 1 diabetes switched to CSII.^[@B26]^ The role of glucose variability in the risk of developing chronic diabetes complications is still a matter of debate,^[@B24],[@B25],[@B27]^ but reducing variability could be considered a reasonable additional benefit of any antidiabetes therapeutic strategy.^[@B28]^

In addition to greater convenience for patients, as well as the reduced risk of missed insulin doses, it may be speculated that the advantages of CSII therapy arise mainly from the more favorable pharmacokinetics and pharmacodynamics of the basal insulin regimen; the daily basal--bolus ratio increased in CSII-treated patients, compared with those receiving MDI.^[@B3]^ It is noteworthy that, although patients on CSII therapy had access to a bolus calculator, this was used very rarely. Another advantage of CSII relates to the ability to obtain data on adherence to pump therapy, whereas adherence cannot be monitored in MDI users. Optimal adherence to insulin therapy is of paramount importance for maximizing treatment efficacy, and adherence in less compliant patients might be improved by switching to pump therapy.

Our study has some limitations. CGM data could not be obtained from the whole cohort of patients, although the characteristics of the patients for whom glucose profile data were available did not differ from those of the full randomized cohort. In addition, CGM is still not used routinely to evaluate glucose control in clinical practice, and its role in clinical studies is evolving. We are aware that longer periods of CGM data may be preferred to reflect variability, and this may be considered in future studies.^[@B29]^ Limitations associated with postprandial glucose assessment, including variations in meal patterns between countries and possible omission of lunchtime insulin doses, have been referred to above.

In summary, compared with MDI, CSII treatment in suboptimally controlled patients with type 2 diabetes provides a significant improvement in glucose profile, with increased time spent within target ranges and less exposure to hyperglycemia, without increasing time spent in hypoglycemia.
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